Truist Securities Maintains Buy on Abivax, Lowers Price Target to $135

Benzinga Newsdesk www.benzinga.com Negative 53.7%

Neg 53.7% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $140 to $135.